This page covers Epistaxis thesis topics across clinical profile, risk factors and severity assessment; diagnostic nasal endoscopy and anatomical correlations; haematological, medication and systemic associations; treatment modalities and early outcomes; and special populations, aetiologies and clinico-radiological or histopathological evaluation for MS Otorhinolaryngology candidates. The emphasis is on ENT epistaxis research topics that can be completed within one thesis period using routine clinical examination, nasal endoscopy, complete blood count and coagulation testing where indicated, medication history, clinically indicated imaging, haemostatic treatment records and short-term outcomes. A shortlisted question should then be converted into a focused MS ENT epistaxis protocol and a submission-ready MS Otorhinolaryngology synopsis.
Last reviewed and updated: September 2026 · 2026–27 admissions
Not the ENT subspeciality you need? Ent on epistaxis is one section of our full ENT collection — the hub page lists every subspeciality, each with its own free topic list. Updated September 2026.
Browse all ENT Thesis Topics →📌 Updated for 2026–2027 MS Otorhinolaryngology Epistaxis admissions
The research framework was reviewed for spontaneous and recurrent epistaxis, endoscopic localisation, systemic and medication-related risk, topical and packing-based haemostasis, endoscopic arterial control, paediatric and elderly epistaxis, trauma and sinonasal causes.
Select Generate Protocol → beside any title in the list above and receive a submission-ready document built around that topic, containing all eighteen components:
Already have your thesis title?
Generate the full ent on epistaxis protocol directly — objectives, methodology, sample size, statistics, timeline, references and annexures.
Generate your protocolAlongside ent on epistaxis protocols and synopses, support is also available for departmental presentations, journal club presentations, ethics committee presentations, and posters and oral presentations for medical conferences — for postgraduate residents, board trainees and research scholars across India and the GCC. Prepared by a practising doctor with long experience in medical publishing and thesis supervision.
Enquire on WhatsApp →Ent on epistaxis research outside India
The topics above work as research questions anywhere — what changes is the document the institution expects, and who approves it before data collection begins. The Gulf equivalent of an Indian synopsis is the ent on epistaxis research proposal submitted to an institutional review board, and it ordinarily carries three sections an Indian synopsis does not: a Gantt chart, a budget and resources section, and a Declaration of Helsinki statement.
Board and residency programmes — country by country
Saudi Arabia — SCFHS and the Saudi Board. Residency and fellowship training under the Saudi Commission for Health Specialties includes a research project with a set timeline, and the ent on epistaxis research proposal is the document prepared at the outset and cleared by the institutional review board before recruitment starts.
United Arab Emirates — DHA, DOH Abu Dhabi and MOHAP. Residents training in Dubai, Abu Dhabi and the northern emirates prepare an ent on epistaxis research protocol for their programme and submit it for institutional review board approval before any data are collected.
Qatar — DHP (formerly QCHP) and Hamad Medical Corporation. A ent on epistaxis IRB proposal is reviewed before recruitment, with the ethics section written to the institution's own template rather than a generic one.
Bahrain — NHRA. Trainees turning ent on epistaxis research topics into a project need the proposal cleared by their institutional research and ethics committee before fieldwork begins.
Oman — OMSB. Residency programmes under the Oman Medical Specialty Board include a research component, and the ent on epistaxis research proposal is the document assessed at the start of it.
Kuwait — KIMS. A ent on epistaxis study protocol goes to the institutional committee for approval before the project begins.
Arab Board programmes across the region. The Arab Board carries its own research requirement irrespective of the host country, and the ent on epistaxis proposal follows the same structure throughout.
Postgraduate degrees — Malaysia, the Gulf and beyond
Malaysia — MMed, the National Medical Research Register and MREC. A ent on epistaxis dissertation proposal for a Master of Medicine programme carried out in a Ministry of Health facility must be registered on the NMRR and approved by the Medical Research and Ethics Committee before the study begins, and the guidance asks for submission four to six months ahead of data collection. Every investigator on the study team registers on the NMRR as well, so the methodology, ethics and team sections are written in far more detail than an Indian synopsis requires.
PhD and Master's candidates elsewhere. University programmes generally require a full ent on epistaxis research proposal of roughly 6,000 to 10,000 words, with an extended literature review, a theoretical framework and a detailed methodology chapter.
PhD and MMed proposals are written individually by a medical doctor and revised until the supervisor accepts them. They are not produced by the automated protocol generator.
Enquire about an ent on epistaxis PhD or MMed proposal →🔥 Trending research areas in Epistaxis for 2026–27
Current epistaxis research increasingly focuses on less traumatic haemostasis, medication-specific management and timely escalation for bleeding that does not respond to first-line treatment.
An epistaxis protocol must define the clinical population, first or recurrent episode, spontaneous or secondary bleeding, anatomical site, baseline severity, haemodynamic status, medication exposure, laboratory testing, haemostatic intervention and the exact outcome window. Anterior and posterior epistaxis, trauma-related bleeding, postoperative bleeding and bleeding from a sinonasal mass should not be pooled without a prespecified clinical reason.
Severity must be defined independently of treatment choice. Nasal packing, admission, cauterisation, transfusion and surgical intervention are management decisions influenced by clinician preference, available equipment, medication exposure, age, comorbidity and local escalation protocols. They can be studied as outcomes, but they should not be the only variables used to define how severe the bleed was at presentation.
The baseline assessment must precede haemostatic treatment. Blood pressure, pulse, haemoglobin where clinically indicated, active bleeding site, estimated bleeding duration and medication exposure should be recorded before packing, cauterisation, topical haemostatic treatment or resuscitation alters the clinical picture. Later values should be labelled as post-treatment or outcome measurements.
An epistaxis synopsis can state that the study will evaluate risk factors, nasal-endoscopic findings, medication associations, treatment success or early rebleeding. The full protocol must convert those aims into reproducible definitions for bleeding site, severity, haemodynamic instability, anticoagulant and antiplatelet exposure, endoscopic examination, laboratory testing, intervention type, treatment success and recurrence.
For comparative treatment studies, the protocol should document why each treatment was selected because localised anterior bleeding amenable to cautery differs from diffuse or posterior bleeding requiring packing or surgery. For recurrent epistaxis, the recurrence interval and minimum number of previous episodes should be prespecified. For anticoagulant-related studies, the exact drug and indication should be recorded rather than using a single broad medication category.
Sample size should follow the primary endpoint. A prevalence or clinical-profile study requires an expected proportion and desired precision; a comparative haemostatic study requires an expected difference in treatment success or rebleeding; and a diagnostic study requires enough patients with and without the prespecified target condition according to the reference standard.
Treatment comparisons must account for confounding by severity and indication. Patients with posterior bleeding, anticoagulant exposure, haemodynamic instability or an unidentified bleeding point are more likely to receive packing, admission or surgical intervention. Comparing their outcomes directly with patients selected for simple cautery can make the more intensive treatment appear less successful because the underlying disease was more severe.
Recurrent episodes from the same patient are repeated observations and should not automatically be treated as independent participants. Multiple candidate predictors should be limited relative to the number of severe events or rebleeding outcomes. If a local severity score or prediction threshold is created and tested in the same dataset, it should be described as internally derived rather than externally validated.
Choose a question that matches the number of epistaxis patients seen in the outpatient department or emergency service and uses information already collected during routine care. Clinical severity, endoscopic bleeding-site localisation, anticoagulant or antiplatelet exposure, nasal packing, cauterisation, early rebleeding and paediatric recurrent epistaxis are usually feasible. Refractory cases requiring arterial ligation or embolisation may need a retrospective or multicentre design if annual numbers are low.
Suitable designs include descriptive and analytical cross-sectional studies, comparative studies, case-control studies, prospective observational cohorts, diagnostic-accuracy studies and retrospective treatment-outcome reviews. A study measuring baseline features and then observing treatment success or rebleeding is prospective observational even when follow-up lasts only hours or a few days.
Settle the definition of an epistaxis episode, anatomical site, severity variables, index time, medication classification, indications for laboratory testing, endoscopic assessment, primary treatment outcome and rebleeding interval. Also specify whether management is determined entirely by routine clinical judgement because this affects how comparative treatment results can be interpreted.
Use objective baseline variables whenever possible, such as haemodynamic status, duration or persistence of active bleeding, anatomical site, haemoglobin when clinically indicated, recurrent presentation and requirement for resuscitation. Packing, admission, transfusion or surgery can be important outcomes but are partly treatment decisions. A protocol should therefore avoid defining severe epistaxis only as the group that received more intensive treatment.
The synopsis is the concise institutional submission describing the epistaxis question, objectives, design and broad methods. The protocol is the operational document that fixes baseline severity, bleeding-site classification, medication exposure, endoscopic assessment, laboratory definitions, treatment categories, success criteria, recurrence interval, confounders, missing-data rules and statistical analysis.
Active haemorrhage must be stabilised immediately and treatment should never be delayed to complete research questionnaires, photographs, endoscopy or laboratory sampling. Anticoagulant or antiplatelet medication should not be stopped, continued or restarted solely for research purposes; such decisions belong to the treating clinical team after considering the bleeding severity and the indication for antithrombotic therapy. Research-only computed tomography, angiography, embolisation, additional coagulation testing or venepuncture requires specific justification and approval.
Prospective participants should provide informed consent once clinically stable, with guardian consent and age-appropriate assent for paediatric participants according to institutional policy. Identifiable nasal-endoscopic photographs or video require separate consent. The escalation pathway should be predefined for haemodynamic instability, uncontrolled posterior bleeding, major haemoglobin reduction, suspected coagulopathy, recurrent unilateral bleeding suggestive of a mass, juvenile nasopharyngeal angiofibroma or another clinically important finding requiring urgent management.
The sharpest error is circularly defining severe epistaxis by the treatment chosen and then studying the same treatment as though it resulted from an independent severity predictor. A patient may undergo packing, admission or surgery because of local practice, anticoagulant exposure, clinician preference or inability to identify a bleeding point rather than because of one uniform biological severity threshold.
The protocol should therefore record objective baseline severity before treatment and analyse management choice separately. Comparative treatment studies should also recognise confounding by indication because patients selected for packing, endoscopic arterial control or embolisation are inherently different from patients suitable for simple cauterisation.
An MS Otorhinolaryngology thesis is usually a focused residency dissertation based on one epistaxis population, diagnostic pathway or short-term treatment outcome that can be completed within one training period. A PhD project may involve multicentre emergency-care research, haemostatic-device evaluation, implementation science, interventional radiology, health economics or development and external validation of a prediction model.
Residents outside the Indian MS pathway should verify dissertation or research requirements with the relevant training authority and institution. Emergency-care research, antithrombotic medication governance, procedural consent, ethics review, data privacy, supervision and completion milestones should follow the applicable local programme.
Register after confirming case volume, baseline severity variables, bleeding-site assessment, medication classification, treatment pathway, primary outcome and rebleeding window, but before prospective research-specific data collection begins. For retrospective work, fix the study period and outcome definitions before reviewing treatment success so that patients are not selectively included according to response already known.
Found a topic that fits your department?
Generate its full protocol — objectives, methodology, sample size, statistics, timeline, references and annexures — in editable format.
Generate your protocol